{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pegylated+interferon+alfa-2a&page=2",
    "query": {
      "intervention": "Pegylated interferon alfa-2a",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 199,
    "total_pages": 20,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pegylated+interferon+alfa-2a&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pegylated+interferon+alfa-2a&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-01T20:36:46.383Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01051921",
      "title": "Study of CTS-1027 in Combination With Pegylated Interferon and Ribavirin in Hepatitis C Virus (HCV) Null-Responders",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "CTS-1027",
          "type": "DRUG"
        },
        {
          "name": "Pegylated interferon",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Conatus Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 67,
      "start_date": "2010-01",
      "completion_date": "2011-12",
      "has_results": true,
      "last_update_posted_date": "2012-04-16",
      "last_synced_at": "2026-10-01T20:36:46.383Z",
      "location_count": 14,
      "location_summary": "La Jolla, California • San Diego, California • Denver, Colorado + 10 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01051921"
    },
    {
      "nct_id": "NCT01648140",
      "title": "Dose Ranging of GSK2336805 in Combination Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C, Chronic"
      ],
      "interventions": [
        {
          "name": "GSK2336805 40 mg",
          "type": "DRUG"
        },
        {
          "name": "GSK2336805 60 mg",
          "type": "DRUG"
        },
        {
          "name": "Pegylated interferon alpha-2a",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        },
        {
          "name": "Telaprevir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 286,
      "start_date": "2012-08-01",
      "completion_date": "2014-07-16",
      "has_results": true,
      "last_update_posted_date": "2017-06-02",
      "last_synced_at": "2026-10-01T20:36:46.383Z",
      "location_count": 18,
      "location_summary": "Dothan, Alabama • Anaheim, California • Los Angeles, California + 15 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01648140"
    },
    {
      "nct_id": "NCT01241760",
      "title": "VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Genotype 1 Chronic Hepatitis C",
        "Treatment Naive"
      ],
      "interventions": [
        {
          "name": "Ribavirin",
          "type": "DRUG"
        },
        {
          "name": "Telaprevir",
          "type": "DRUG"
        },
        {
          "name": "Pegylated interferon alfa-2a",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Infectious Diseases BVBA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 744,
      "start_date": "2010-12",
      "completion_date": "2012-11",
      "has_results": true,
      "last_update_posted_date": "2014-06-04",
      "last_synced_at": "2026-10-01T20:36:46.383Z",
      "location_count": 37,
      "location_summary": "La Jolla, California • Los Angeles, California • San Diego, California + 34 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01241760"
    },
    {
      "nct_id": "NCT00047879",
      "title": "Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioma"
      ],
      "interventions": [
        {
          "name": "PEG-interferon alfa-2b",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Thalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2002-10",
      "completion_date": "2009-06",
      "has_results": true,
      "last_update_posted_date": "2011-10-26",
      "last_synced_at": "2026-10-01T20:36:46.383Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00047879"
    },
    {
      "nct_id": "NCT01329978",
      "title": "Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C, Chronic"
      ],
      "interventions": [
        {
          "name": "Sofosbuvir",
          "type": "DRUG"
        },
        {
          "name": "RBV",
          "type": "DRUG"
        },
        {
          "name": "PEG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 332,
      "start_date": "2011-03",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2014-05-26",
      "last_synced_at": "2026-10-01T20:36:46.383Z",
      "location_count": 44,
      "location_summary": "Montgomery, Alabama • Jonesboro, Arkansas • Anaheim, California + 36 more",
      "locations": [
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Coronado",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01329978"
    },
    {
      "nct_id": "NCT00800735",
      "title": "A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis C, Chronic"
      ],
      "interventions": [
        {
          "name": "Pegylated-interferon alfa-2a",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2009-04",
      "completion_date": "2012-03",
      "has_results": true,
      "last_update_posted_date": "2013-10-30",
      "last_synced_at": "2026-10-01T20:36:46.383Z",
      "location_count": 11,
      "location_summary": "Sacramento, California • San Francisco, California • Lutherville, Maryland + 8 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Lutherville",
          "state": "Maryland"
        },
        {
          "city": "Manhasset",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00800735"
    },
    {
      "nct_id": "NCT02816684",
      "title": "Pegasys VR: Integrating Virtual Humans in the Treatment of Child Social Anxiety",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anxiety Disorders"
      ],
      "interventions": [
        {
          "name": "Pegasys-VR",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Social Effectiveness Therapy for Children",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Central Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "7 Years to 12 Years"
      },
      "enrollment_count": 43,
      "start_date": "2016-06",
      "completion_date": "2018-08",
      "has_results": false,
      "last_update_posted_date": "2018-10-19",
      "last_synced_at": "2026-10-01T20:36:46.383Z",
      "location_count": 1,
      "location_summary": "Orlando, Florida",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02816684"
    },
    {
      "nct_id": "NCT01483742",
      "title": "A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C, Chronic"
      ],
      "interventions": [
        {
          "name": "RO5024048",
          "type": "DRUG"
        },
        {
          "name": "danoprevir",
          "type": "DRUG"
        },
        {
          "name": "peginterferon alfa-2a [Pegasys]",
          "type": "DRUG"
        },
        {
          "name": "ribavirin",
          "type": "DRUG"
        },
        {
          "name": "ritonavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 43,
      "start_date": "2012-04",
      "completion_date": "2013-09",
      "has_results": false,
      "last_update_posted_date": "2016-08-01",
      "last_synced_at": "2026-10-01T20:36:46.383Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Anaheim, California • Coronado, California + 11 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Coronado",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01483742"
    },
    {
      "nct_id": "NCT01369212",
      "title": "Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis B"
      ],
      "interventions": [
        {
          "name": "Tenofovir",
          "type": "DRUG"
        },
        {
          "name": "Peginterferon-alfa 2a and tenofovir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 201,
      "start_date": "2012-11",
      "completion_date": "2021-03-08",
      "has_results": true,
      "last_update_posted_date": "2023-04-28",
      "last_synced_at": "2026-10-01T20:36:46.383Z",
      "location_count": 20,
      "location_summary": "Los Angeles, California • San Francisco, California • Honolulu, Hawaii + 11 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01369212"
    },
    {
      "nct_id": "NCT01142700",
      "title": "A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Hepatitis C Virus Genotype 1"
      ],
      "interventions": [
        {
          "name": "BMS-824393",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Peginterferon Alpha-2a",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 0,
      "start_date": "2010-07",
      "completion_date": "2010-12",
      "has_results": false,
      "last_update_posted_date": "2011-03-15",
      "last_synced_at": "2026-10-01T20:36:46.383Z",
      "location_count": 11,
      "location_summary": "Coronado, California • San Diego, California • Washington D.C., District of Columbia + 8 more",
      "locations": [
        {
          "city": "Coronado",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01142700"
    }
  ]
}